Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan B…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Early Phase 1

Clinical phase

Completed

Recruitment status

not reported

Planned enrollment

2024-03-07

Primary-completion proxy

Executive view

NCT05281718 evaluates Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization) in Hemophilia A. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin, assessed over 1 Year.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT05281718 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hemophilia A landscape. Drug & Asset MCP drug_fetch was queried for Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization), while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT05281718	Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization)	Early Phase 1 / Completed	Sponsor not reported	United States	Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhib… 1 Year	2024-03-07
NCT05441553	VGB-R04	Phase 1/2 / Unknown status	Shanghai Vitalgen Biopharma Co., Ltd.	China	Incidence of adverse events Baseline up to Week 52	2025-01-01
NCT05421429	Armocibart	Phase 2 / Completed	Suzhou Alphamab Co., Ltd.	China	Frequency and severity of treatment emergent adverse events(TEAEs) Day 1 up to Day 85	2024-01-17
NCT05365217	Nonacog beta pegol	Phase 3 / Completed	Novo Nordisk A/S	China	Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis… From start of treatment (week 0) until end of treatment (up to week 5…	2024-04-11
NCT05306418	Denecimig	Phase 3 / Completed	Novo Nordisk A/S	United States, Japan, United Kingdom, Switzerland, Portugal, Spain, Russia, India, Canada, South Korea, Netherlands, China, Taiwan Province, Poland, South Africa, Italy, Israel, Lithuania, Germany	Number of treatment emergent adverse events From treatment initiation to follow up visit (week 0 to week 72)	2024-11-13

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT05281718 is a Early Phase 1, completed study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin” over “1 Year.” The retrieved endpoint description is: Peak thrombin is a thrombin generation profile. The investigators will compare the peak thrombin obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with aPCC and rFVIIa on emicizumab prophylaxis..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Hemophilia A. These records do not establish direct evidence for NCT05281718 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization) is indexed as Recombinant coagulation factor with target not reported biology and a global stage of Approved. The asset profile lists The Japan Blood Products Organization as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT05281718
Protocol source: https://clinicaltrials.gov/study/NCT05281718
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.

Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization) in Hemophilia A is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin and 2024-03-07 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP